Search Results

Canada's AtomVie Opens Large-Scale Radiopharmaceutical R&D and Manufacturing Facility in Hamilton

On September 4, AtomVie Global Radiopharma, a radiopharmaceutical contract development and manufacturing organization, announced the official opening of its new state-of-the-art production facility at 10 Aeropark Boulevard, Hamilton, Ontario, Canada. The facility is designed to support the full-spectrum translation of radiopharmaceuticals from early-stage research and development, through clinical development, to commercial manufacturing. According to reports, the new facility represents an investment of over $160 million and spans 72,300 square feet, making it one of the largest single-site radiopharmaceutical R&D CDMO facilities in North America. The facility offers production capabilities ranging from low-throughput to high-throughput, increasing AtomVie's overall production capacity by more than tenfold, with dedicated spaces configurable to meet clients' subsequent R&D and commercialization needs.

2026-09-05

Radionuclide Ward Officially Launched at Xuguan Campus of Suzhou Nuclear Industry General Hospital under CNNC Medical

On September 3, the radionuclide ward of the Nuclear Medicine Department at the Xuguan Campus of Suzhou Nuclear Industry General Hospital, affiliated with CNNC Medical, was officially inaugurated and put into operation. The ward addresses the standardized radionuclide therapy needs of patients with tumors, thyroid diseases, and endocrine disorders, providing inpatient treatment services with isolation and protection conditions. According to reports, the newly launched radionuclide ward is equipped with radiation protection facilities and intelligent monitoring systems, enabling fully enclosed ward management, treatment process monitoring, and multi-level protection. Following the ward's commissioning, the Nuclear Medicine Department will expand from its previous examination-focused service model into a closed-loop service chain integrating radionuclide diagnosis, drug therapy, isolated hospitalization, and research follow-up, enhancing its capacity to manage complex and critically ill patients...

2026-09-05

China's largest single-building oncology nuclear medicine center to be completed and put into operation in Luzhou, Sichuan

On September 2, the "Myriad Weather in Sichuan · Starting Strong for the '15th Five-Year Plan'" Luzhou special press conference was held in Chengdu. The conference disclosed that China's largest single-building oncology nuclear medicine center is about to be completed and put into operation in Luzhou, Sichuan. Construction site of the Oncology Nuclear Medicine Center of the Affiliated Hospital of Southwest Medical University. The center is a key project of Sichuan Province's regional medical centers. The project has a total investment of 310 million yuan, covers an area of approximately 15,000 square meters, and plans more than 160 beds. It will integrate functions including nuclear medicine molecular imaging, nuclear drug R&D and preparation, radionuclide therapy, tumor radiotherapy, and specialized oncology diagnosis and treatment, and will be built into...

2026-09-03

West Physics Acquires U.S. Medical Physics Services Provider RTS, Expanding Nuclear Medicine and Radiation Safety Service Network

West Physics Consulting, LLC, a U.S. provider of medical and health physics consulting services, announced on September 2, 2026, that it has acquired Radiographic Testing Services, Inc. (RTS). Headquartered in Albany, New York, RTS primarily provides medical physics services covering nuclear medicine, diagnostic radiology, radiation oncology, and Certified Radiological Equipment Safety Officer (CRESO)-related services. West Physics stated that this acquisition will integrate the strengths of both companies in customer service, quality management, and technical capabilities. Upon completion of the transaction, the company will add a new office in Albany, New York, and further expand its presence in Albany, New York...

2026-09-03

Sejong City Requests National Support for Proton Cancer Therapy Center Budget

On September 2, 2026, the Democratic Party of Korea and Sejong City held their first budget policy consultation meeting at the Sejong City Government to discuss key agenda items and budget support for the city. At the meeting, Sejong City Mayor Cho Sang-ho requested the Democratic Party's attention to several issues, including securing national funding for the construction of a cancer proton therapy center, improving the general grant system for Sejong City, and promoting the passage of the Special Act on the Administrative Capital within the year. After the closed-door consultation, a relevant spokesperson stated in a briefing that the meeting proposed allocating 300 million KRW each in the next year's national budget for a feasibility study on the construction of the cancer proton therapy center and for the formulation of the basic plan for the National Central Bioresource Center.

2026-09-02

Prostate cancer becomes most common cancer among men in South Korea, Lu-177 PSMA therapy reaches cumulative 200 procedures

Prostate cancer incidence in South Korea has continued to rise, making it the most common cancer among men in the country. Meanwhile, a novel nuclear medicine treatment for metastatic prostate cancer—Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) radioligand therapy—is accumulating more clinical cases. Seoul St. Mary's Hospital Uro-Oncology Center stated on September 1 that since performing South Korea's first Lu-177 PSMA treatment on November 2, 2020, the center had administered a cumulative total of 200 such treatments to 84 patients with metastatic prostate cancer as of the 21st of last month. Metastatic castration-resistant prostate cancer refers to a state in which prostate cancer continues to progress despite androgen suppression therapy. As the disease advances, patients have fewer treatment options and a worse prognosis, making it essential to select appropriate treatment modalities and sequencing based on prior treatment history and physical condition.

2026-09-02

Ionetix begins routine supply of astatine-211 in North America, expanding sources of isotopes for targeted alpha therapy

Ionetix, a U.S. medical isotope producer, recently announced that it has begun routine supply of astatine-211 (At-211) in North America. The company stated that this development expands the supply sources of At-211 and is expected to support its further application in preclinical research and clinical development. Ionetix noted that it believes it is the first non-academic commercial supplier of At-211 in the United States. Ionetix produces At-211 at its facility in Lansing, Michigan, leveraging its proprietary cyclotron technology. The company currently operates a 30 MeV cyclotron equipped with optimized target technology, aiming to support the production of clinical-grade At-211. The company stated that its production ca...

2026-09-02

FDA Grants Breakthrough Therapy Designation to JBS-003 for Guiding De-escalated Radiotherapy in HPV-Positive Oropharyngeal Cancer

On September 1, Juniper Biosciences announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its hypoxia tracer JBS-003. The product, 18F-Fluoromisonidazole (FMISO), is intended to identify tumor hypoxia and guide de-escalated radiotherapy in patients with HPV-positive oropharyngeal cancer (OPC). JBS-003 is licensed from Memorial Sloan Kettering Cancer Center (MSK). According to information released by the company, the tracer is based on F-MISO PET molecular imaging technology and can visualize specific hypoxic features within tumors. Tumor hypoxia is considered to be associated with radioresistance; by imaging hypoxic regions, clinicians can stratify patients by risk and...

2026-09-02

Dankook University Hospital Introduces Next-Generation Digital PET-CT System to Enhance Precision Diagnosis of Cancer and Other Diseases

Dankook University Hospital announced on September 1 that it has introduced GE HealthCare's next-generation digital PET-CT system, the OMNI Legend 32, to enhance precision diagnostic capabilities for a wide range of diseases, including cancer, brain disorders, and cardiac conditions. PET-CT is an important nuclear medicine diagnostic imaging modality. During the examination, a radiopharmaceutical is injected into the patient, and the system observes metabolic activity through positron emission tomography (PET) while simultaneously confirming anatomical structures via computed tomography (CT), thereby providing imaging evidence for clinical diagnosis. According to the hospital, the newly introduced OMNI Legend 32 employs AI-based image reconstruction technology to visualize small lesions with greater clarity, assisting physicians in making more accurate assessments...

2026-09-01

Beijing Jiluntai's ¹⁷⁷Lu-JLT003 Injection Receives IND Approval for Treatment of Integrin αvβ3-Positive Malignant Tumors

Beijing Jiluntai Pharmaceutical Co., Ltd. has recently achieved progress in radiopharmaceutical R&D. Its self-developed Class 1 innovative therapeutic radiopharmaceutical ¹⁷⁷Lu-JLT003 Injection (generic name: ¹⁷⁷Lu-AB-3PRGD2) has obtained the Clinical Trial Approval (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), intended for the treatment of integrin αvβ3-positive malignant tumors. ¹⁷⁷Lu-AB-3PRGD2 is a therapeutic radiopharmaceutical targeting integrin αvβ3. Integrin αvβ3 is highly expressed on various solid tumor cells and tumor neovascular endothelial cells, while showing low expression in normal tissues, a characteristic that...

2026-09-01

Bayer Presents Phase III Data for Iodine-124 PET Tracer: High Sensitivity Shown in Cardiac Amyloidosis Diagnosis

At the 2026 European Society of Cardiology Congress, Bayer presented results from the Phase III REVEAL study of its investigational PET radiotracer iodine-124 evuzamitide (I-124 evuzamitide). Data showed that the tracer met the study's primary endpoints in diagnostic sensitivity and specificity when used for imaging in patients with suspected cardiac amyloidosis. The REVEAL study, sponsored by Brigham and Women's Hospital, is a multicenter, open-label, single-arm Phase III clinical trial conducted at 18 sites in the United States, enrolling 170 adult patients with suspected cardiac amyloidosis. Following a single intravenous injection of I-124 evuzamitide, subjects underwent cardiac and...

2026-09-01

Defence Therapeutics Expands Radiopharmaceutical R&D Program to Evaluate Alpha and Beta Emitter Applications

MONTREAL, Quebec, Canada — Biotechnology company Defence Therapeutics Inc. recently announced the expansion of its radiopharmaceutical R&D program to include α and β radioisotopes in its evaluation scope, further validating the application potential of its proprietary Accum® technology in precision oncology. Defence Therapeutics is a publicly traded biotechnology company developing next-generation oncology treatments centered on its Accum® precision drug delivery platform. The company stated that the Accum® technology is designed to facilitate the entry of drug payloads into the intracellular compartment, thereby improving delivery efficiency. This expansion of the radiopharmaceutical program...

2026-09-01

CNNC Headway's 13C-Urea Synthesis Control Method Patent Wins China Patent Excellence Award

On August 28, the China National Intellectual Property Administration officially released the decision on the 26th China Patent Award, and CNNC Headway's invention patent "A 13C-Urea Synthesis Control Method" won the China Patent Excellence Award. This patented technology addresses key technical bottlenecks in the batch production of carbon [13C]-urea API, establishing a set of synthesis control methods that provide technical support for the large-scale and stable production of the relevant API. The application of this technology helps enhance the self-sufficiency capability of the domestic urea [13C] breath diagnostic industry chain. CNNC Headway has long been deeply engaged in the breath diagnostic field, with sustained investment in innovative R&D, quality control, clinical adaptation, and industry chain layout...

2026-09-01

Japanese research team visualizes cellular metabolic changes during fracture healing using hyperpolarized MRI

August 21, 2026, Gifu Pharmaceutical University and Gifu University announced that a multi-institutional Japanese research team successfully visualized changes in the redox state of skeletal progenitor cells during fracture healing in living mice using hyperpolarized magnetic resonance imaging technology. The findings were published online on August 15, 2026, in the British academic journal *npj Imaging*. The study was led by Takuya Kubo, a graduate student in the Department of Pharmacology at Gifu Pharmaceutical University, Professor Eiichi Hinoi, and related research teams at Gifu University, in collaboration with the University of Tokyo, Osaka University, the Research Institute of National Rehabilitation Center for Persons with Disabilities, and other institutions. After a fracture occurs, a tissue called a...

2026-08-31

Chonnam National University Hospital in Hwasun, South Korea, Adopts Deepnoid's Chest X-ray AI Interpretation Solution "M4CXR"

Deepnoid announced on August 31 that it has signed a supply contract with Chonnam National University Hospital in Hwasun, South Korea, to provide the hospital with its AI-based chest X-ray preliminary opinion generation solution, M4CXR. This contract is part of the "AI Medical System Support Project for Regional Responsible Medical Institutions" promoted by the Ministry of Health and Welfare of South Korea. Chonnam National University Hospital in Hwasun plans to improve the work efficiency of medical staff in interpreting chest X-ray images and further enhance the quality of medical services through the introduction of M4CXR. A representative from the Hwasun branch of Chonnam National University Hospital stated that introducing a generative AI-based image interpretation support system is of great significance for improving the quality of public medical services...

2026-08-31